{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "laboratory",
      "workplace testing"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34789010",
  "DateCompleted": {
    "Year": "2021",
    "Month": "12",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "12",
    "Day": "14"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "11",
        "Day": "18"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.4155/bio-2021-0241"
    ],
    "Journal": {
      "ISSN": "1757-6199",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "24",
        "PubDate": {
          "Year": "2021",
          "Month": "Dec"
        }
      },
      "Title": "Bioanalysis",
      "ISOAbbreviation": "Bioanalysis"
    },
    "ArticleTitle": "Testing in the workplace: finding a path through a pandemic.",
    "Pagination": {
      "StartPage": "1785",
      "EndPage": "1788",
      "MedlinePgn": "1785-1788"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "BioAgilytix Labs, Durham, NC\u00a027613, USA."
          }
        ],
        "LastName": "Briscoe",
        "ForeName": "Jameson",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Bioanalysis",
    "NlmUniqueID": "101512484",
    "ISSNLinking": "1757-6180"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "instrumentation",
        "methods"
      ],
      "DescriptorName": "COVID-19 Testing"
    },
    {
      "QualifierName": [
        "legislation & jurisprudence"
      ],
      "DescriptorName": "Centers for Disease Control and Prevention, U.S."
    },
    {
      "QualifierName": [
        "organization & administration"
      ],
      "DescriptorName": "Drug Industry"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Physical Distancing"
    },
    {
      "QualifierName": [
        "organization & administration"
      ],
      "DescriptorName": "Point-of-Care Testing"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "United States"
    },
    {
      "QualifierName": [
        "organization & administration"
      ],
      "DescriptorName": "Workplace"
    }
  ],
  "CoiStatement": "\n<b>Financial & competing interests disclosure</b>\n. The author works as an employee at BioAgilytix, a contract research organization which specializes in bioanalysis. BioAgilytix\u00a0provides\u00a0COVID-19 testing as part of its business model, however, this done through direct contract with drug development companies and not outside the industry. The author\u00a0has\u00a0no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript."
}